Company: KVACU
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0001213900-25-021314
Chunk: 349

Company: Keen Vision Acquisition Corp.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 2
Chunk 349
---
 and a guest professor at the Peking University Health Science Center (formerly known as Beijing Medical University) from January
1994 to December 2000. From October 1989 to October 1994, Prof. Yu was a research associate and later senior research associate at Stanford
University’s Department of Pathology. Prior to this, from July 1984 to September 1989, he was an assistant academic researcher at
the University of California, San Francisco.

Prof. Yu earned his Bachelor
of Science, his Master of Science, and his Doctor of Philosophy degrees from the University of Saskatchewan.

We believe Prof. Yu is well-qualified
to serve as a member of our board of directors given his experience, industry expertise, and network.

Director Independence

Nasdaq requires that a majority
of our board must be composed of “Independent Directors.” Currently, Mr. Peter Ding, Mr. William Chu, and Prof. Albert
Yu would each be considered an “Independent Director” under the Nasdaq listing rules, which is defined generally as a person
other than an officer or employee of the company or its subsidiaries or any other individual having a relationship, which, in the opinion
of the company’s board of directors would interfere with the director’s exercise of independent judgment in carrying out the
responsibilities of a director. Our Independent Directors will have regularly scheduled meetings at which only Independent Directors are
present.

We will only enter into a
business combination if it is approved by a majority of our Independent Directors. Additionally, we will only enter into transactions
with our officers and directors and their respective affiliates that are on terms no less favorable to us than could be obtained from
independent parties. Any related-party transactions must also be approved by our audit committee and a majority of disinterested Independent
Directors.

Board Committees

The Board has a standing audit,
nominating and compensation committee. The independent directors oversee director nominations. Each audit committee and compensation committee
has a charter, which was filed with the SEC as exhibits to the Registration Statement on Form S-1 on February 9, 2023.

31

Audit Committee

We have established an audit
committee of the board of directors, which consists of Mr. Peter Ding, Mr. William Chu, and Prof. Albert Yu, each of whom is an independent
director under Nasdaq’s listing standards. Mr. Peter Ding is the Chairperson of the audit committee. The audit committee’s
duties, which are specified in our Audit